PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.66%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-35.70%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
20.21%
EBIT growth 1.25-1.5x CRON.TO's 17.47%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
20.21%
Operating income growth above 1.5x CRON.TO's 9.08%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
113.92%
Net income growth above 1.5x CRON.TO's 37.71%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
99.57%
EPS growth above 1.5x CRON.TO's 37.89%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
99.57%
Diluted EPS growth above 1.5x CRON.TO's 37.89%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.42%
Share count expansion well above CRON.TO's 0.27%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.42%
Diluted share count expanding well above CRON.TO's 0.27%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
81.64%
OCF growth above 1.5x CRON.TO's 49.04%. David Dodd would confirm a clear edge in underlying cash generation.
77.49%
FCF growth above 1.5x CRON.TO's 44.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
594.48%
5Y revenue/share CAGR under 50% of CRON.TO's 1543.61%. Michael Burry would suspect a significant competitive gap or product weakness.
323.94%
3Y revenue/share CAGR above 1.5x CRON.TO's 163.20%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-161.58%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-776.11%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-559.39%
Negative 3Y OCF/share CAGR while CRON.TO stands at 64.84%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
284.96%
10Y net income/share CAGR of 284.96% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
43.41%
Positive 5Y CAGR while CRON.TO is negative. John Neff might view this as a strong mid-term relative advantage.
-93.73%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
5088.46%
Equity/share CAGR of 5088.46% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
710.77%
5Y equity/share CAGR at 50-75% of CRON.TO's 1058.98%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
47.80%
3Y equity/share CAGR above 1.5x CRON.TO's 22.89%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.47%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-7.35%
Inventory is declining while CRON.TO stands at 7.52%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-3.72%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-0.42%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.47%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-34.39%
Our R&D shrinks while CRON.TO invests at 6.51%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-20.17%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.